Olanzapine in the treatment of depression with psychotic features: A prospective open-label study

International Journal of Psychiatry in Clinical Practice

Volumn 12, Issue 3, 2008, Pages 202-209

  Adli, Mazda ^a   Wiethoff, Katja ^a   Baethge, Christopher ^b   Pfennig, Andrea ^c   Stamm, Thomas ^a   Bauer, Michael ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Antidepressants; Atypical antipsychotics; Combination treatment; Delusional depression; Extrapyramidal side effects; Olanzapine

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CITALOPRAM; CLOMIPRAMINE; DIAZEPAM; DOXEPIN; HALOPERIDOL; LITHIUM; MAPROTILINE; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PERAZINE; REBOXETINE; SERTRALINE; SULPIRIDE; TRAZODONE; VENLAFAXINE;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DEPRESSION; DEPRESSIVE PSYCHOSIS; DRUG EFFICACY; FEMALE; HOSPITAL PATIENT; HUMAN; HYPERPHAGIA; HYPERTRICHOSIS; MAJOR DEPRESSION; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TACHYCARDIA; TINNITUS; TREATMENT RESPONSE; WEIGHT GAIN; XEROSTOMIA;

EID: 48249149515     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500801911144     Document Type: Article

References (65)

1. Baethge C, Baldessarini RJ, Freudenthal K, Streeruwitz A, Bauer M, Bschor T. Hallucinations in bipolar disorder: characteristics and comparison to unipolar depression and schizophrenia. Bipolar Disord 2005;7:136-45.
2. Keck PE, McElroy SL, Strakowski SM, Soutullo CA. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J Clin Psychiatry 2000;61(Suppl 4):33-8.
3. Meyers BS, Greenberg R. Late-life delusional depression. J Affect Disord 1986;11:133-7.
4. Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry 1992;149:733-45.
5. Bond TC, Rothschild AJ, Lerbinger J, Schatzberg AF. Delusional depression, familiy history, and DST response: a pilot study. Biol Psychiatry 1986;21:1239-46.
6. Nelson JC, Davis JM. DST studies in psychotic depression: a meta-analysis. Am J Psychiatry 1997;154:1497-503.
7. Posener JA, DeBattista C, Williams GH, Kraemer HC, Kalehzan M, Schatzberg AF. 24-hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. Arch Gen Psychiatry 2000;57:755-60.
8. Aberg-Wistedt A, Wistedt B, Bertilsson L. Higher CSF levels of HVA and 5-HIAA in delusional compared to nondelusional depression. Arch Gen Psychiatry 1985;42:925-6.
9. Mazure CM, Bowers MB, Hoffman F, Miller KB, Nelson JC. Plasma catecholamine metabolites in subtypes of major depression. Biol Psychiatry 1987;22:1469-72.
10. Meyers BS, Alexopoulos GS, Kakuma T, et al. Decreased dopamine beta-hydroxylase activity in unipolar geriatric delusional depression. Biol Psychiatry 1999;45:448-52.
11. Mod L, Rhimer Z, Magyar I, Arato M, Alfoldi A, Bagdy G. Serum DBH activity in psychotic vs. nonpsychotic unipolar and bipolar depression. Psychiatry Res 1986;19:331-3.
12. Charney DS, Nelson JC. Delusional and nondelusional unipolar depression: further evidence for distinct subtypes. Am J Psychiatry 1981;138:328-33.
13. O'Neal BL, Smith CL, Trivedi MH. Evaluation of newer treatment interventions for psychotic depression. Curr Psychiatry Rep 2000;2:305-9.
14. Coryell W, Tsuang MT. Primary unipolar depression and the prognostic importance of delusions. Arch Gen Psychiatry 1982;39:1181-4.
15. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000;157(Suppl):1-45.
16. Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ, World Federation of Societies Biological Psychiatry Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002;3:5-43.
17. Iwanami A, Oyamada S, Shirayama Y, Kamijima K. Algorithms for the pharmacotherapy of psychotic depression. Psychiatry Clin Neurosci 1999;53(Suppl):45-8.
18. Mukherjee S, Rosen AM, Caracci G, Shukla S. Persistent tardive dyskinesia in bipolar patients. Arch Gen Psychiatry 1986;43:342-6.
19. Rush M, Diamond F, Alpert M. Depression as a risk factor in tardive dyskinesia. Biol Psychiatry 1982;17:387-92.
20. Yassa R, Ghadirian AM, Schwartz G. Prevalence of tardive dyskinesia in affective disorder patients. J Clin Psychiatry 1983;44:410-2.
21. Kukopulos A, Reginaldi D, Laddomoda P, Floris G, Serra G, Tondo L. Course of the manic-depressive cycle and changes caused by treatments. Pharmacopsychiatry 1980;13:156-67.
22. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
23. Tollefson GD, Sanger TM, Lu Y, Thieme ME. Depressive signs and symptoms in schizophrenia. A prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998;55:250-8.
24. Mathews J, Garcia KS, Mintun MA, Sheline YI. Antidepressant efficacy of olanzapine as monotherapy in major depressive disorder, without psychosis: a pilot study. Psychiatry Res 2006;31:149-55.
25. König F, v Hippel C, Petersdorf T, Neuhoffer-Weiss M, Wolfersdorf M, Kaschka WP. First experiences in combination therapy using olanzapine with SSRIs (citalopram, paroxetine) in delusional depression. Neuropsychobiology 2001;43:170-4.
26. Matthews JD, Bottonari KA, Polania LM. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. J Clin Psychiatry 2002;63:1164-70.
27. Nelson EB, Rielage E, Welge JA, Keck PE. An open trial of olanzapine in the treatment of patients with psychotic depression. Ann Clin Psychiatry 2001;13:147-51.
28. Rothschild AJ, Bates KS, Boehringer KL, Syed A. Olanzapine response in psychotic depression. J Clin Psychiatry 1999;60:116-8.
29. Adli M, Rossius W, Bauer M. Olanzapine in the treatment of depressive disorders with psychotic disorders. Nervenarzt 1999;70:68-71 (in German).
30. Debattista C, Solvason B, Belanoff J, Schatzberg AF. Treatment of psychotic depression. Am J Psychiatry 1997;154:1625-6 (letter).
31. Malhi GS, Checkley SA. Olanzapine in the treatment of psychotic depression. Br J Psychiatry 1999;174:460-3.
32. Schmitt A, Braus DF. Effective treatment of depressive disorder with psychotic symptoms by Olanzapine combination therapy. Dtsch Med Wochenschr 2000;125:1526-9 (in German).
33. Weisler RH, Ahearn EP, Davidson JRT, Wallace CD. Adjunctive use of olanzapine in mood disorders: five case reports. Ann Clin Psychiatr 1997;9:259-62.
34. Rothschild AJ, Williamson DJ, Tohen MF, et al. A double-blind, randomized study of olanzapine and olanzapine/ fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol 2004;24:365-73.
35. Ghaemi SN, Cherry EL, Katzow JA, Goodwin FK. Does olanzapine have antidepressant properties? A retrospective preliminary study. Bipolar Disord 2000;2:196-9.
36. Zarate CA Jr, Narendran R, Tohen M, et al. Clinical predictors of acute response with olanzapine in psychotic mood disorders. J Clin Psychiatry 1998;59:24-8.
37. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-4.
38. Bauer M, Linden M, Smolka M, et al. Effectiveness of an algorithm-guided treatment regimen compared to treatment as usual: a randomized controlled study of inpatients with depression. Submitted
39. World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD-10). Geneva: World Health Organization; 1992.
40. Bech P, Rafaelsen OJ. The Melancholia Scale: development, consistency, validity and utility. In: Sartorius N, Ban TA, editors. Assessment of depression. Berlin: Springer; 1986; 1986. p 259.
41. Hiller W, v. Zerssen D, Mombour W, Wittchen HU. Inpatient Multidimensional Psychiatric Scale. Deutsche Bearbeitung. Weinheim: Beltz Test; 1986.
42. Overall JE , Gorham DR. 06 BPRS. Brief Psychiatric Rating Scale. In: Guy W, Bonat RR, editors. ECDEU assessment battery. Rev. Ed. Rockville, MD; 1976.
43. Guy W. Early Clinical Drug Evaluation Unit (ECDEU) assessment manual for psychopharmacology. Revised. NIMH publication DHEW publ no. (Adm) 76-338. Bethesda MD: National Institute of Mental Health; 1976. p 217-22.
44. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-6.
45. Simpson GN, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212(Suppl 44):11-9.
46. Lane RD, Glazer WM, Hansen TE, Berman WH, Kramer SI. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. J Nerv Ment Dis 1985;173:353-7.
47. Ilardi SS, Craighead WE. Personality pathology and response to somatic treatments for major depression: a critical review. Depression 1995;2:200-17.
48. Shea MT, Pilkonis PA, Beckham E, et al. Personality disorders and treatment outcome in the NIMH treatment of depression collaborative research program. Am J Psychiatry 1990;147:711-8.
49. Kool S, Schoevers R, de Maat S, et al. Efficacy of pharmacotherapy in depressed patients with and without personality disorders: a systematic review and meta-analysis. J Affect Disord 2005;88:269-78.
50. Hillert A, Maier W, Wetzel H, Benkert O. Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome: a functional approach. Pharmacopsychiatry 1992;25:213-7.
51. Lane HY, Chang WH. Risperidone monotherapy for psychotic depression unresponsive to other treatments. J Clin Psychiatry 1998;59:624.
52. Miodownik C, Lerner V. Risperidone in the treatment of psychotic depression. Clin Neuropharmacol 2000;23:335-7.
53. Goto M, Yoshimura R, Kakihara S, et al. Risperidone in the treatment of psychotic depression. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:701-7.
54. Catapano-Friedmann L. Effectiveness of quetiapine in the management of psychotic depression in an adolescent boy with bipolar disorder, mixed, with psychosis. J Child Adolesc Psychopharmacol 2001;11:205-6.
55. Padla D. Quetiapine resolves psychotic depression in an adolescent boy. J Child Adolesc Psychopharmacol 2001;11:207-8.
56. Zarate CA Jr, Rothschild A, Fletcher KE, Madrid A, Zapatel J. Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry 2000;61:185-9.
57. Konstantinidis A, Hrubos W, Nirnberger G, et al. Quetiapine in combination with citalopram in patients with unipolar psychotic depression. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(1):242-7.
58. Mueller-Siecheneder F, Müller MJ, Hillert A, Szegedi A, Wetzel H, Benkert O. Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol 1998;18:111-20.
59. Chan CH, Janicak PG, Davis JM, Altman E, Andriukaitis S, Hedeker D. Response of psychotic and and nonpsychotic depressed patients to tricyclic antidepressants. J Clin Psychiatry 1987;48:197-200.
60. Kroessler DK. Relative efficacy rates for therapies of delusional depression. Convuls Ther 1985;1:173-82.
61. Parker G, Roy K, Hadzi-Pavlovic D, Pedic F. Psychotic (delusional) depression: a meta-analysis of physical treatment. J Affect Disord 1992;24:17-24.
62. Mulsant BH, Sweet RA, Rosen J, et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. J Clin Psychiatry 2001;62:597-604.
63. Wijkstra J, Lijmer J, Balk, F, Geddes J, Nolen WA. Pharmacological treatment for psychotic depression. Cochrane Database Syst Rev 2005;4:CD004044. DOI: 10.1002/14651858.CD004044.pub2.
64. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 2005;353:1209-23.
65. Cipriani A, Geddes JR, Furukawa TA, Barbui C. Metareview on short-term effectiveness and safety of antidepressants for depression: an evidence-based approach to inform clinical practice. Can J Psychiatry 2007;52:553-62.